BRAND NAME (Select/Unselect)
COUNTRIES (Select/Unselect)
THERAPEUTIC AREA (Select/Unselect)
CONTENT (Select/Unselect)
APPLY FILTERS
EXPORT

View selection

Progress Date advice Recommendation Type of limitation
Type of limitation
- - -
Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
TIMELINES Close all timelines
04 Apr 2016
EAMS
23 Nov

23 Nov
EAMS
05 May

Rationale and Comments

Type of limitation Recommended with limitations
Access scheme
PAS
  • Increased Overall Survival vs everolimus
  • Improved QoL
  • Some uncertainty in the economic analysis, but acceptable for an orphan equivalent medicine

05 May
EAMS
07 Oct

07 Oct
05 Oct
27 Dec
NICE 233 days
SMC 396 days
SMC 186 days
France / TC 267 days
2017
  • EMA decision
  • HTA decision
  • Reimbursement decision
  • Accepted
  • Restricted
  • Rejected
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range